Real-world data on primary cutaneous lymphoproliferative disorders following SARS-CoV-2 vaccination: A multicentre experience from tertiary referral hospitals
J Eur Acad Dermatol Venereol
.
2023 Apr;37(4):e451-e455.
doi: 10.1111/jdv.18806.
Epub 2022 Dec 19.
Authors
Gianluca Avallone
1
2
3
,
Carlo Alberto Maronese
2
3
,
Claudio Conforti
4
,
Paolo Fava
1
,
Luigi Gargiulo
5
6
,
Angelo Valerio Marzano
2
3
,
Cesare Massone
7
,
Luca Mastorino
1
,
Andrea Paradisi
8
9
,
Alessandro Pileri
10
11
,
Pietro Quaglino
1
,
Nathalie Rizzo
12
,
Simone Ribero
1
,
Gabriele Roccuzzo
1
,
Gianluca Tavoletti
2
3
,
Carlo Alberto Vignoli
5
6
,
Iris Zalaudek
4
,
Emilio Berti
2
3
,
Silvia Alberti-Violetti
2
3
Affiliations
1
Department of Medical Sciences, University of Turin, Dermatology Clinic, Turin, Italy.
2
Dermatology Unit, Department of Internal Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
3
Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
4
Dermatology Clinic, Maggiore Hospital of Trieste, Trieste, Italy.
5
Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.
6
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
7
Dermatology Unit, Galliera Hospital, Genoa, Italy.
8
UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
9
Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
10
Dermatology Unit, IRCCS of Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
11
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
12
Department of Pathology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
PMID:
36469002
PMCID:
PMC9877594
DOI:
10.1111/jdv.18806
No abstract available
Publication types
Multicenter Study
Letter
MeSH terms
COVID-19 Vaccines* / adverse effects
COVID-19* / epidemiology
COVID-19* / prevention & control
Humans
SARS-CoV-2
Tertiary Care Centers
Vaccination
Substances
COVID-19 Vaccines